XTAE
BIOV
Market cap4mUSD
Jul 10, Last price
90.30ILS
1D
-3.63%
1Q
506.04%
Jan 2017
-99.98%
IPO
-99.99%
Name
Bio-View Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bio-View Ltd, founded in 2000 and headquartered in Rehovot, Israel, is a developer, manufacturer, and global distributor of advanced automated cell imaging and analysis systems. These sophisticated solutions are utilized by clinical and research laboratories worldwide, specifically in the fields of cytology, cytogenetics, and pathology. The company's extensive product lineup includes: Accord: A semi-automated fluorescent imaging and analysis workbench microscope station. Accord Plus: An automatic fluorescent imaging system capable of real-time scanning, analysis, and sorting of diverse FISH (Fluorescence In Situ Hybridization) samples. Allegro Plus: Another automatic fluorescent imaging system engineered to pinpoint various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. DUET-3: An imaging and analysis platform featuring an automated barcode reader, which streamlines the processing of multiple test types within a single scan batch. DeNovo: An automated scanning system dedicated to the precise detection, analysis, and characterization of circulating tumor cells found in peripheral blood. Solo Workstation & Solo Touch Workstation: These are offline and standalone workstations, respectively, providing advanced tools for reviewing and analyzing test results remotely from the microscope. SoloWeb: A comprehensive web-based solution that enables remote analysis, reporting, and expert consultation on cases scanned using Bio-View's systems. Furthermore, Bio-View Ltd has established a strategic partnership with ANGLE plc to jointly develop a liquid biopsy circulating tumor cell HER2 assay, specifically targeting breast cancer.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||